Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatm...(an or objectives; the ability of the com...),Health

Date:2/6/2009

an or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2007 and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, each as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

    Idenix Pharmaceuticals Contacts:
    Amy Sullivan 617-995-9838 (investors)
    Teri Dahlman 617-995-9905 (media)

    GlaxoSmithKline Contacts:

    UK Media enquiries:                  Philip Thomson  (020) 8047 5502
                                         Alice Hunt      (020) 8047 5502
                                         David Outhwaite (020) 8047 5502
                                         Stephen Rea     (020) 8047 5502

    US Media enquiries:                  Nancy Pekarek    (919) 483 2839
                                         Mary Anne Rhyne  (919) 483 2839
                                         Kevin Colgan     (919) 483 2839
                                         Sarah Alspach    (215) 751 7709

    European Ana
'/>"/>
SOURCE  Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related medicine technology :

1. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
4. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
8. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody